BioMarin to acquire Prosensa

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has concluded it can successfully make the case to gain approval for drisapersen to treat Duchenne muscular dystrophy after it acquires Prosensa Holding N.V. (NASDAQ:RNA) for $680 million in cash up front and up to $160 million

Read the full 419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE